Eleven analysts have given shares of Pacira Pharmaceuticals a consensus "Buy" rating, according to an AnalystRatings.NET report.
Eight research analysts have assigned a buy rating to Pacira, and one gave the stock a hold rating. According to the report, the average 12-month target price among analysts that have issues ratings on the stock in the last year is $105.21.
Analysts across numerous research firms have recently improved Pacira's ratings. Shares of Pacira were upgraded from "neutral" to "outperform" ratings, according to analysts at Zacks, and they currently have a $109.50 price target on the stock. Analysts at Wedbush and Canaccord Genuity have also raised their price target on shares of Pacira Pharmaceuticals, with Wedbush increasing stock prices from $98.00 to $110.00 and Canaccord Genuity up to $114.00.
Eight research analysts have assigned a buy rating to Pacira, and one gave the stock a hold rating. According to the report, the average 12-month target price among analysts that have issues ratings on the stock in the last year is $105.21.
Analysts across numerous research firms have recently improved Pacira's ratings. Shares of Pacira were upgraded from "neutral" to "outperform" ratings, according to analysts at Zacks, and they currently have a $109.50 price target on the stock. Analysts at Wedbush and Canaccord Genuity have also raised their price target on shares of Pacira Pharmaceuticals, with Wedbush increasing stock prices from $98.00 to $110.00 and Canaccord Genuity up to $114.00.